Literature DB >> 24135138

Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers.

Julio C Ricarte-Filho, Sheng Li, Maria E R Garcia-Rendueles, Cristina Montero-Conde, Francesca Voza, Jeffrey A Knauf, Adriana Heguy, Agnes Viale, Tetyana Bogdanova, Geraldine A Thomas, Christopher E Mason, James A Fagin.   

Abstract

Exposure to ionizing radiation during childhood markedly increases the risk of developing papillary thyroid cancer. We examined tissues from 26 Ukrainian patients with thyroid cancer who were younger than 10 years of age and living in contaminated areas during the time of the Chernobyl nuclear reactor accident. We identified nonoverlapping somatic driver mutations in all 26 cases through candidate gene assays and next-generation RNA sequencing. We found that 22 tumors harbored fusion oncogenes that arose primarily through intrachromosomal rearrangements. Altogether, 23 of the oncogenic drivers identified in this cohort aberrantly activate MAPK signaling, including the 2 somatic rearrangements resulting in fusion of transcription factor ETS variant 6 (ETV6) with neurotrophic tyrosine kinase receptor, type 3 (NTRK3) and fusion of acylglycerol kinase (AGK) with BRAF. Two other tumors harbored distinct fusions leading to overexpression of the nuclear receptor PPARγ. Fusion oncogenes were less prevalent in tumors from a cohort of children with pediatric thyroid cancers that had not been exposed to radiation but were from the same geographical regions. Radiation-induced thyroid cancers provide a paradigm of tumorigenesis driven by fusion oncogenes that activate MAPK signaling or, less frequently, a PPARγ-driven transcriptional program.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24135138      PMCID: PMC3809792          DOI: 10.1172/JCI69766

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  32 in total

1.  Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells.

Authors:  M N Nikiforova; J R Stringer; R Blough; M Medvedovic; J A Fagin; Y E Nikiforov
Journal:  Science       Date:  2000-10-06       Impact factor: 47.728

2.  Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children.

Authors:  Y E Nikiforov; J M Rowland; K E Bove; H Monforte-Munoz; J A Fagin
Journal:  Cancer Res       Date:  1997-05-01       Impact factor: 12.701

3.  Preferential induction of RET/PTC1 rearrangement by X-ray irradiation.

Authors:  T Mizuno; K S Iwamoto; S Kyoizumi; H Nagamura; T Shinohara; K Koyama; T Seyama; K Hamatani
Journal:  Oncogene       Date:  2000-01-20       Impact factor: 9.867

Review 4.  Cancer after nuclear fallout: lessons from the Chernobyl accident.

Authors:  Dillwyn Williams
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

5.  Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications.

Authors:  H M Rabes; E P Demidchik; J D Sidorow; E Lengfelder; C Beimfohr; D Hoelzel; S Klugbauer
Journal:  Clin Cancer Res       Date:  2000-03       Impact factor: 12.531

6.  Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma.

Authors:  Cristina Tognon; Stevan R Knezevich; David Huntsman; Calvin D Roskelley; Natalya Melnyk; Joan A Mathers; Laurence Becker; Fatima Carneiro; Nicol MacPherson; Doug Horsman; Christopher Poremba; Poul H B Sorensen
Journal:  Cancer Cell       Date:  2002-11       Impact factor: 31.743

7.  ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation.

Authors:  Kevin B Morrison; Cristina E Tognon; Mathew J Garnett; Cheri Deal; Poul H B Sorensen
Journal:  Oncogene       Date:  2002-08-22       Impact factor: 9.867

8.  High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident.

Authors:  S Klugbauer; E Lengfelder; E P Demidchik; H M Rabes
Journal:  Oncogene       Date:  1995-12-21       Impact factor: 9.867

9.  Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident.

Authors:  L Fugazzola; S Pilotti; A Pinchera; T V Vorontsova; P Mondellini; I Bongarzone; A Greco; L Astakhova; M G Butti; E P Demidchik
Journal:  Cancer Res       Date:  1995-12-01       Impact factor: 12.701

10.  Gene rearrangement and Chernobyl related thyroid cancers.

Authors:  M Santoro; G A Thomas; G Vecchio; G H Williams; A Fusco; G Chiappetta; V Pozcharskaya; T I Bogdanova; E P Demidchik; E D Cherstvoy; L Voscoboinik; N D Tronko; A Carss; H Bunnell; M Tonnachera; J Parma; J E Dumont; G Keller; H Höfler; E D Williams
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

View more
  76 in total

Review 1.  Emerging Gene Fusion Drivers in Primary and Metastatic Central Nervous System Malignancies: A Review of Available Evidence for Systemic Targeted Therapies.

Authors:  Priscilla K Brastianos; Franziska Maria Ippen; Umbreen Hafeez; Hui K Gan
Journal:  Oncologist       Date:  2018-04-27

2.  Mutation in BRAF and Other Members of the MAPK Pathway in Papillary Thyroid Carcinoma in the Pediatric Population.

Authors:  Ryan J Gertz; Yuri Nikiforov; William Rehrauer; Lee McDaniel; Ricardo V Lloyd
Journal:  Arch Pathol Lab Med       Date:  2016-02       Impact factor: 5.534

3.  Comparative Histopathologic Analysis of "Radiogenic" and "Sporadic" Papillary Thyroid Carcinoma: Patients Born Before and After the Chernobyl Accident.

Authors:  Tetiana I Bogdanova; Vladimir A Saenko; Alina V Brenner; Liudmyla Yu Zurnadzhy; Tatiana I Rogounovitch; Ilya A Likhtarov; Sergii V Masiuk; Leonila M Kovgan; Victor M Shpak; Geraldine A Thomas; Stephen J Chanock; Kiyohiko Mabuchi; Mykola D Tronko; Shunichi Yamashita
Journal:  Thyroid       Date:  2018-07       Impact factor: 6.568

4.  Identification of oncogenic mutations and gene fusions in the follicular variant of papillary thyroid carcinoma.

Authors:  David G McFadden; Dora Dias-Santagata; Peter M Sadow; Kerry D Lynch; Carrie Lubitz; Samuel E Donovan; Zongli Zheng; Long Le; A J Iafrate; Gilbert H Daniels
Journal:  J Clin Endocrinol Metab       Date:  2014-08-22       Impact factor: 5.958

Review 5.  The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.

Authors:  Valentina De Falco; Francesca Carlomagno; Hong-Yu Li; Massimo Santoro
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2017-05-10       Impact factor: 4.690

6.  Investigation of the Relationship Between Radiation Dose and Gene Mutations and Fusions in Post-Chernobyl Thyroid Cancer.

Authors:  Alexey A Efanov; Alina V Brenner; Tetiana I Bogdanova; Lindsey M Kelly; Pengyuan Liu; Mark P Little; Abigail I Wald; Maureen Hatch; Liudmyla Y Zurnadzy; Marina N Nikiforova; Vladimir Drozdovitch; Rebecca Leeman-Neill; Kiyohiko Mabuchi; Mykola D Tronko; Stephen J Chanock; Yuri E Nikiforov
Journal:  J Natl Cancer Inst       Date:  2018-04-01       Impact factor: 13.506

7.  Recurrent BRAF Gene Rearrangements in Myxoinflammatory Fibroblastic Sarcomas, but Not Hemosiderotic Fibrolipomatous Tumors.

Authors:  Yu-Chien Kao; Valentina Ranucci; Lei Zhang; Yun-Shao Sung; Edward A Athanasian; David Swanson; Brendan C Dickson; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2017-11       Impact factor: 6.394

Review 8.  Kinase gene fusions: roles and therapeutic value in progressive and refractory papillary thyroid cancer.

Authors:  Mian Liu; Pei Chen; Hui-Yu Hu; Deng-Jie Ou-Yang; Rooh-Afza Khushbu; Hai-Long Tan; Peng Huang; Shi Chang
Journal:  J Cancer Res Clin Oncol       Date:  2021-01-02       Impact factor: 4.553

Review 9.  Biologic and Clinical Perspectives on Thyroid Cancer.

Authors:  James A Fagin; Samuel A Wells
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

Review 10.  Update: the status of clinical trials with kinase inhibitors in thyroid cancer.

Authors:  Samuel A Wells; Massimo Santoro
Journal:  J Clin Endocrinol Metab       Date:  2014-01-13       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.